The Government of India released data on those who contracted the novel coronavirus disease (COVID-19) even after being vaccinated:
Bharat Biotech International Ltd said April 21, 2021 that its Covaxin showed 78 per cent efficacy against mild, moderate and severe novel coronavirus disease (COVID-19), while releasing the second round of interim results.
The company has developed the vaccine along with the Indian Council of Medical Research, which earlier in the day claimed that Covaxin is effective against “multiple variants” of the SARS-C0V-2 virus, including its “double mutant”strain. It didn’t cite any research paper to substantiate.
Bharat Biotech said the vaccine’s efficacy against severe COVID-19 disease was cent per cent with an impact on reduction in hospitalisations.
The first round of interim results, announced in March 2021, pegged efficacy at 80.6 per cent. The next, final round is expected in June.
There, however, has been no preprint or peer-reviewed research paper on the product’s efficacy yet.
Serum Institute of India announced Wednesday (April 21, 2021) that its Covishield vaccine would be priced at Rs 600 per dose at private hospitals and Rs 400 per dose at state government establishments.
Vaccines against the novel coronavirus disease (COVID-19) are to be allowed into the market without government control from May 1, the Centre said earlier this week.